Article

Adam Friedman, MD: Dermatology Treatments Show Promise as COVID-19 Medications

Author(s):

With the majority of the scientific research community focused, a COVID-19 vaccine could be on the horizon.

Never before has so much attention been paid to a coronavirus.

While researchers previously have not had much luck in developing a vaccine for the family of viruses, the majority of the scientific research community has zeroed in on the coronavirus disease 2019 (COVID-19), giving hope that a vaccine is possible sooner rather than later.

With a significant number of vaccines already in clinical trials, there is also ongoing research testing both new and existing drugs that could potentially help patients once they contract the virus.

In an interview with HCPLive®, Adam Friedman, MD, Professor & Interim Chair of Dermatology at The George Washington University School of Medicine and Health Sciences, said because there is so much attention being paid to the virus globally, a vaccine could be on the horizon.

However, the success of any potential vaccine relies on whether or not the virus mutates or changes in the near future.

Friedman, who recently participated in a free online webinar hosted by HCPLive® and sister publication Dermatology Times titled “Derm Clinical Updates: Keeping Up with COVID-19,” also discussed how dermatologists can be essential in the research of existing medications that could be effective in treating COVID-19.

Related Videos
Shawn Kwatra, MD: Making the Connection Between Prurigo Nodularis, Atopic Dermatitis, and Itch
Highlighting Recent Therapies for Dermatologists, with James Del Rosso, DO
James Del Rosso, DO: Discussing What’s New in the Medicine Chest for Dermatologists
What to Look Forward To at the Fall Clinical Dermatology Conference, with Raj Chovatiya, MD, PhD
Uncovering the Role of COVID-19 in Rheumatic Disease, with Leonard Calabrese, DO
Ashfaq Marghoob, MD: Artificial Intelligence, Smartphone Use for Pigmented Lesion Classification
Major Diagnostic Challenges for Pigmented Lesions, with Ashfaq Marghoob, MD
Discussing Interim Findings on Nemolizumab for Atopic Dermatitis, with Diamant Thaçi, MD
Responding to FDA Approval of Lebrikizumab for Atopic Dermatitis, with Andrew Alexis, MD, MPH
Atypical Clinical Presentations of Blistering Disease, with Donna Culton, MD, PhD
© 2024 MJH Life Sciences

All rights reserved.